Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Literature DB >> 24186319

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Etienne Lengline¹, Kheïra Beldjord, Hervé Dombret, Jean Soulier, Nicolas Boissel, Emmanuelle Clappier.

Abstract

Entities: Disease Gene

Keywords: B-cell precursor acute lymphoblastic leukemia; EBF1-PDGFRB; refractory; tyrosine kinase inhibitor

Mesh：

Substances：

Year: 2013 PMID： 24186319 PMCID： PMC3815191 DOI： 10.3324/haematol.2013.095372

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

10 in total

1. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Authors: Brent W Weston; Melissa A Hayden; Kathryn G Roberts; Susan Bowyer; Johann Hsu; George Fedoriw; Kathleen W Rao; Charles G Mullighan
Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544

2. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.

Authors: M Carroll; M H Tomasson; G F Barker; T R Golub; D G Gilliland
Journal: Proc Natl Acad Sci U S A Date: 1996-12-10 Impact factor: 11.205

3. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.

Authors: Marion Strullu; Nadège Corradini; Marie Audrain; Jean-Luc Orsonneau; Daniel Bouige; Patrick Thomare; Claudine Vermot-Desroches; Adeline Mansuy; Arnaud Legrand; Jean-Christophe Rozé; Mohamad Mohty; Françoise Méchinaud
Journal: Leuk Lymphoma Date: 2010-08

4. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Authors: Kathryn G Roberts; Ryan D Morin; Jinghui Zhang; Martin Hirst; Yongjun Zhao; Xiaoping Su; Shann-Ching Chen; Debbie Payne-Turner; Michelle L Churchman; Richard C Harvey; Xiang Chen; Corynn Kasap; Chunhua Yan; Jared Becksfort; Richard P Finney; David T Teachey; Shannon L Maude; Kane Tse; Richard Moore; Steven Jones; Karen Mungall; Inanc Birol; Michael N Edmonson; Ying Hu; Kenneth E Buetow; I-Ming Chen; William L Carroll; Lei Wei; Jing Ma; Maria Kleppe; Ross L Levine; Guillermo Garcia-Manero; Eric Larsen; Neil P Shah; Meenakshi Devidas; Gregory Reaman; Malcolm Smith; Steven W Paugh; William E Evans; Stephan A Grupp; Sima Jeha; Ching-Hon Pui; Daniela S Gerhard; James R Downing; Cheryl L Willman; Mignon Loh; Stephen P Hunger; Marco A Marra; Charles G Mullighan
Journal: Cancer Cell Date: 2012-08-14 Impact factor: 31.743

5. Failure of B-cell differentiation in mice lacking the transcription factor EBF.

Authors: H Lin; R Grosschedl
Journal: Nature Date: 1995-07-20 Impact factor: 49.962

6. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

Authors: Aurélie Caye; Kheïra Beldjord; Kelly Mass-Malo; Séverine Drunat; Jean Soulier; Virginie Gandemer; André Baruchel; Yves Bertrand; Hélène Cavé; Emmanuelle Clappier
Journal: Haematologica Date: 2012-10-12 Impact factor: 9.941

7. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

Authors: T R Golub; G F Barker; M Lovett; D G Gilliland
Journal: Cell Date: 1994-04-22 Impact factor: 41.582

8. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors: Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal: Lancet Oncol Date: 2009-01-08 Impact factor: 41.316

9. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors: Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal: N Engl J Med Date: 2009-01-07 Impact factor: 91.245

10. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors: Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245

10 in total

62 in total

1. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

Authors: Nicolas Duployez; Guillaume Grzych; Benoît Ducourneau; Martin Alarcon Fuentes; Nathalie Grardel; Thomas Boyer; Wadih Abou Chahla; Bénédicte Bruno; Brigitte Nelken; Emmanuelle Clappier; Claude Preudhomme
Journal: Haematologica Date: 2015-12-17 Impact factor: 9.941

2. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Authors: Chan Y Cheah; Kate Burbury; Jane F Apperley; Francoise Huguet; Vincenzo Pitini; Martine Gardembas; David M Ross; Donna Forrest; Philippe Genet; Philippe Rousselot; Nigel Patton; Graeme Smith; Cynthia E Dunbar; Sawa Ito; Ricardo C T Aguiar; Olatoyosi Odenike; Alla Gimelfarb; Nicholas C P Cross; John F Seymour
Journal: Blood Date: 2014-03-31 Impact factor: 22.113

Review 3. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.

Authors: Ching-Hon Pui
Journal: Front Med Date: 2014-12-15 Impact factor: 4.592

4. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.

Authors: Judith M Boer; João R M Marchante; William E Evans; Martin A Horstmann; Gabriele Escherich; Rob Pieters; Monique L Den Boer
Journal: Haematologica Date: 2015-06-04 Impact factor: 9.941

5. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Authors: Judith M Boer; Jasper E Koenders; Bronno van der Holt; Carla Exalto; Mathijs A Sanders; Jan J Cornelissen; Peter J M Valk; Monique L den Boer; Anita W Rijneveld
Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941